(Q33928690)

30 July 2017

1 reference

title

The newer macrolides: azithromycin and clarithromycin (English)

1 reference

30 July 2017

0 references

1 reference

Zuckerman JM

1

1 reference

30 July 2017

1 June 2000

1 reference

Infectious Disease Clinics of North America

30 July 2017

1 reference

30 July 2017

14

1 reference

30 July 2017

2

1 reference

30 July 2017

449-62, x

1 reference

Clarithromycin 250 mg b.i.d. for 5 or 10 days in the treatment of adult patients with purulent bronchitis

30 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970257-9

7 January 2021

Macrolides versus azalides: a drug interaction update

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970257-9

7 January 2021

Azithromycin: the first azalide antibiotic

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970257-9

7 January 2021

Community-acquired pneumonia in adults: guidelines for management. The Infectious Diseases Society of America

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970257-9

7 January 2021

Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment (OCAY) Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970257-9

7 January 2021

Comparison of azithromycin versus clarithromycin in the treatment of patients with lower respiratory tract infection

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970257-9

7 January 2021

Treatment of community-acquired pneumonia. A multicenter, double-blind, randomized study comparing clarithromycin with erythromycin. Canada-Sweden Clarithromycin-Pneumonia Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970257-9

7 January 2021

Effect of moderate or severe hepatic impairment on clarithromycin pharmacokinetics

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970257-9

7 January 2021

A comparison of the efficacy, tolerability and safety of azithromycin and co-amoxiclav in the treatment of sinusitis in adults

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970257-9

7 January 2021

Double-blind comparative trial of ciprofloxacin versus clarithromycin in the treatment of acute bacterial sinusitis. Sinusitis Infection Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970257-9

7 January 2021

Azithromycin. A review of its pharmacological properties and use as 3-day therapy in respiratory tract infections

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970257-9

7 January 2021

Multiple mechanisms of erythromycin resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970257-9

7 January 2021

A comparison of 10 and 14 days of lansoprazole triple therapy for eradication of Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970257-9

7 January 2021

In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970257-9

7 January 2021

The absence of an effect of food on the bioavailability of azithromycin administered as tablets, sachet or suspension

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970257-9

7 January 2021

The pharmacokinetics of azithromycin in human serum and tissues

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970257-9

7 January 2021

The diffusion of clarithromycin and roxithromycin into nasal mucosa, tonsil and lung in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970257-9

7 January 2021

Intravenous azithromycin.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970257-9

7 January 2021

In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970257-9

7 January 2021

Overview of the tolerability profile of clarithromycin in preclinical and clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970257-9

7 January 2021

The Safety and Efficacy of Clarithromycin in Patients with Legionella Pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970257-9

7 January 2021

Multicenter trial of single-dose azithromycin vs. ceftriaxone in the treatment of uncomplicated gonorrhea. Azithromycin Gonorrhea Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970257-9

7 January 2021

Clarithromycin, a unique macrolide. A pharmacokinetic, microbiological, and clinical overview

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970257-9

7 January 2021

Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970257-9

7 January 2021

Comparison of sparfloxacin and clarithromycin in the treatment of acute bacterial maxillary sinusitis. Sparfloxacin Multicenter AMS Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970257-9

7 January 2021

Efficacy of a 1-week regimen of ranitidine bismuth citrate in combination with metronidazole and clarithromycin for Helicobacter pylori eradication

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970257-9

7 January 2021

Clinical toleration and safety of azithromycin

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970257-9

7 January 2021

Guidelines for the management of Helicobacter pylori infection. Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970257-9

7 January 2021

The role of azalide antibiotics in the treatment of chlamydia

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970257-9

7 January 2021

Azithromycin versus cefaclor in the treatment of acute bacterial pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970257-9

7 January 2021

Azithromycin versus amoxicillin/clavulanate in the treatment of acute sinusitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970257-9

7 January 2021

Clarithromycin. A review of its efficacy in the treatment of respiratory tract infections in immunocompetent patients

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970257-9

7 January 2021

Comparative studies of azithromycin in skin and soft-tissue infections and sexually transmitted infections by Neisseria and Chlamydia species

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970257-9

7 January 2021

Single-dose oral azithromycin versus seven-day doxycycline in the treatment of non-gonococcal urethritis in males

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970257-9

7 January 2021

Bacterial resistance to macrolide, lincosamide, and streptogramin antibiotics by target modification

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970257-9

7 January 2021

Intrinsic and unusual resistance to macrolide, lincosamide, and streptogramin antibiotics in bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970257-9

7 January 2021

Comparison of azithromycin and doxycycline in the treatment of non-gonococcal urethritis in men.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970257-9

7 January 2021

Azithromycin compared with cephalexin in the treatment of skin and skin structure infections

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970257-9

7 January 2021

Clarithromycin and omeprazole as helicobacter pylori eradication therapy in patients with H. pylori-associated gastric disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970257-9

7 January 2021

Pharmacokinetics of azithromycin in patients with impaired hepatic function

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970257-9

7 January 2021

Review and comparison of advanced-generation macrolides clarithromycin and dirithromycin

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970257-9

7 January 2021

Introduction: Revolutionary changes in the macrolide and azalide antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970257-9

7 January 2021

Comparison of azithromycin versus clarithromycin in the treatment of patients with upper respiratory tract infections

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970257-9

7 January 2021

Drug interactions with azithromycin and the macrolides: an overview

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970257-9

7 January 2021

The development of macrolides: clarithromycin in perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970257-9

7 January 2021

Efficacy and safety of clarithromycin compared to cefixime as outpatient treatment of lower respiratory tract infections

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970257-9

7 January 2021

Randomized, multicentre study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of adults with mild to moderate community-acquired pneumonia. Azithromycin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970257-9

7 January 2021

Double-blind, multicenter, placebo-controlled evaluation of clarithromycin and omeprazole for Helicobacter pylori-associated duodenal ulcer

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970257-9

7 January 2021

Macrolides with gastrointestinal motor stimulating activity

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970257-9

7 January 2021

Clarithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970257-9

7 January 2021

Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970257-9

7 January 2021

Ranitidine bismuth citrate plus clarithromycin is effective for healing duodenal ulcers, eradicating H. pylori and reducing ulcer recurrence. RBC H. pylori Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970257-9

7 January 2021

Helicobacter pylori: rational management options

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970257-9

7 January 2021

Comparative tolerability of erythromycin and newer macrolide antibacterials in paediatric patients

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970257-9

7 January 2021

Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970257-9

7 January 2021

Optimal duration of therapy combining ranitidine bismuth citrate with clarithromycin and metronidazole in the eradication of Helicobacter pylori infection

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970257-9

7 January 2021

Comparison of azithromycin and erythromycin in the treatment of atypical pneumonias

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970257-9

7 January 2021

The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970257-9

7 January 2021

Resistance to Erythromycin in Group A Streptococci

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970257-9

7 January 2021

Consensus conference. Medical treatment of peptic ulcer disease. Practice guidelines. Practice Parameters Committee of the American College of Gastroenterology

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970257-9

7 January 2021

Azithromycin in the treatment of uncomplicated genital chlamydial infections

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970257-9

7 January 2021

Azithromycin and doxycycline for treatment of Borrelia culture-positive erythema migrans.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970257-9

7 January 2021

Erythema migrans: comparison of treatment with azithromycin, doxycycline and phenoxymethylpenicillin

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970257-9

7 January 2021

Clarithromycin: review of a new macrolide antibiotic with improved microbiologic spectrum and favorable pharmacokinetic and adverse effect profiles

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970257-9

7 January 2021

Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970257-9

7 January 2021

Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. The Laboratory Investigator Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970257-9

7 January 2021

Open study of the safety and efficacy of a single oral dose of azithromycin for the treatment of uncomplicated gonorrhoea in men and women

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970257-9

7 January 2021

Azithromycin and clarithromycin: overview and comparison with erythromycin

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970257-9

7 January 2021

10.1016/S0891-5520(05)70257-9

Identifiers

DOI

1 reference

30 July 2017

1 reference

PubMed ID

10829265